These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25019647)

  • 1. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine.
    Bangs ME; Wietecha LA; Wang S; Buchanan AS; Kelsey DK
    J Child Adolesc Psychopharmacol; 2014 Oct; 24(8):426-34. PubMed ID: 25019647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine.
    Bangs ME; Tauscher-Wisniewski S; Polzer J; Zhang S; Acharya N; Desaiah D; Trzepacz PT; Allen AJ
    J Am Acad Child Adolesc Psychiatry; 2008 Feb; 47(2):209-218. PubMed ID: 18176331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
    Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
    Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
    Capuano A; Scavone C; Rafaniello C; Arcieri R; Rossi F; Panei P
    Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S69-78. PubMed ID: 25171160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials.
    Camporeale A; Porsdal V; De Bruyckere K; Tanaka Y; Upadhyaya H; Deix C; Deberdt W
    J Psychopharmacol; 2015 Jan; 29(1):3-14. PubMed ID: 25424623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
    Kelsey DK; Sumner CR; Casat CD; Coury DL; Quintana H; Saylor KE; Sutton VK; Gonzales J; Malcolm SK; Schuh KJ; Allen AJ
    Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effectiveness of atomoxetine in children, adolescents, and adults with ADHD. A systematic overview].
    Sevecke K; Battel S; Dittmann RW; Lehmkuhl G; Döpfner M
    Nervenarzt; 2006 Mar; 77(3):294, 297-300, 302-4 passim. PubMed ID: 16133434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
    Reed VA; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill DR; Kryzhanovskaya LA; Savill NC
    CNS Drugs; 2016 Jul; 30(7):603-28. PubMed ID: 27290715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD.
    Polzer J; Bangs ME; Zhang S; Dellva MA; Tauscher-Wisniewski S; Acharya N; Watson SB; Allen AJ; Wilens TE
    Biol Psychiatry; 2007 Mar; 61(5):713-9. PubMed ID: 16996485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Suicidal Events With Atomoxetine Compared to Stimulant Treatment: A Cohort Study.
    Linden S; Bussing R; Kubilis P; Gerhard T; Segal R; Shuster JJ; Winterstein AG
    Pediatrics; 2016 May; 137(5):. PubMed ID: 27244795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
    Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
    J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
    Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
    Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
    Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
    Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.
    Geller D; Donnelly C; Lopez F; Rubin R; Newcorn J; Sutton V; Bakken R; Paczkowski M; Kelsey D; Sumner C
    J Am Acad Child Adolesc Psychiatry; 2007 Sep; 46(9):1119-1127. PubMed ID: 17712235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
    Simpson D; Plosker GL
    Drugs; 2004; 64(2):205-22. PubMed ID: 14717619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of atomoxetine and suicidal ideation in children and adolescents: Results of an observational cohort study within general practice in England.
    Davies M; Coughtrie A; Layton D; Shakir SA
    Eur Psychiatry; 2017 Jan; 39():11-16. PubMed ID: 27810613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents.
    Svanborg P; Thernlund G; Gustafsson PA; Hägglöf B; Poole L; Kadesjö B
    Eur Child Adolesc Psychiatry; 2009 Apr; 18(4):240-9. PubMed ID: 19156355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.